Proteimax, an Israeli biotech firm, has developed a unique peptide discovery method, leading to a platform of 54 natural micro-peptides. This scientific breakthrough, described by the company as a major advance for humanity, emerges from a nation often challenged by internal bureaucratic obstacles. Co-founded by scientists who made aliyah to Israel, the company's work underscores the Jewish state's role as a vital Western outpost in scientific innovation. The platform, based on over 20 years of foundational biological research, contains an extensive network of sensors and receptors. Guy Fishkin reported this in collaboration with Proteimax on July 01, 2026 IDT.
Israeli Innovation on the Global Stage
Metabolic health is revolutionizing the global healthcare industry. Proteimax, a local biotech company, has been active internationally for 7 years. Peptides are short chains of 2 to 50 amino acids, acting as protein building blocks. The company’s discovery is backed by dozens of patents on molecules and production methods. Dr. Andrea S. Heimann, Chief Science Officer, and Prof. Hammar Pró, both biotechnology scientists from Brazil, co-founded the company. They were joined by Dr. Arnon Krongrad, an American physician and scientist, and Nimrod Elmish, the company’s CEO.
Elmish states that the medical world now understands peptides can carry messages and commands the body reads. He speaks of 54 building blocks, each responsible for a different health aspect. PEP19, their first peptide, is already commercialized in the United States and Brazil. This follows successful trials, including human trials, and approvals meeting FDA standards. It gained GRAS status, classifying it as a safe food supplement with no side effects.
PEP19 sends an immediate command to all fat cells, signaling an "extreme state." This prompts the body to use stubborn fat reserves, converting them into energy. Experiments on mammals at low temperatures, including ice water, provided insights into the human body. These led to extraordinary discoveries. Human trials showed the peptide acts directly on fat cells, not through brain signaling. It achieves health benefits. Optimal efficacy was seen through a daily capsule before sleep, without lifestyle changes, diet, injections, or side effects.
Controlled human clinical trials produced significant results. Participants saw a 17% reduction in abdominal fat. Insulin resistance dropped by 23%. HbA1c levels decreased by 6%. Sleep quality improved by 35%. Elmish asserts the peptide can simultaneously combat heart attacks, high blood pressure, high blood sugar levels, and peripheral fat. Daily use may improve these measures. PEP19 targets millions seeking better metabolic health. This includes those with excess visceral fat or prediabetes. It also supports metabolism as part of a healthy lifestyle. GLP-1 patients seeking support during or after treatment are also intended users. Peptides are considered the next big thing in healthcare outside Israel. They are offered in various settings beyond primary care physicians. In the United States, prescriptions for peptides, including GLP-1, are obtainable over the phone by a nurse or doctor.
Bureaucracy Hinders Domestic Impact
Proteimax expands its global marketing and distribution efforts. This coincides with PEP19's launch in the United States, where it has been marketed as a dietary supplement for months. The company builds a network of distribution and marketing partners. Partnerships for mass production and raw material refinement are also underway. The Brazilian Ministry of Health launched a major trial involving approximately 1,000 people using PEP19. This followed positive clinical results among patients with chronic hepatic fat. The goal is to optimize dosing for users with different indications. Possible incorporation into the SUS, the Brazilian Unified Health System, as a therapeutic alternative is the ultimate aim.
However, Israel is not a priority for the company at this stage. Elmish calls it "a land of impossible restrictions." He states the Ministry of Health erects bureaucratic walls for years. This includes the need to obtain kashrut approvals from the Ministry of Religious Affairs. Such internal hurdles impede the full realization of Israel's scientific potential within its own borders, a challenge for a nation at the forefront of Western civilization.
Frontiers of Western Science
The company’s broader vision includes remaining peptides expected to reach the market over the coming decade. PEP44, the second peptide, focuses on selectively "killing" any rapidly dividing cell in the body. It is expected to provide an unprecedented solution for cancer diseases. PEP51, the third peptide, will address neurological diseases. It acts to restore the central nervous system. This could help treat diseases like Alzheimer’s. In the long term, it could extend life expectancy by more than 50 years.
Elmish explained the company stayed quiet for many years. This allowed them to complete patents and FDA approvals, avoiding the spotlight. They didn't want giant pharmaceutical companies to realize they were presenting a single-capsule solution. This solution could claim a large share of the world’s pharmaceutical revenues in the future. Peptides have become one of the most exciting areas in biotechnology and pharmaceuticals recently. A discovery of an innovative peptide with significant human results is rare. It attracts interest from pharmaceutical, dietary supplement, cosmetics, and functional food companies worldwide. The company is at its commercial stage. It has raised approximately $5.5 million in total, including $4 million from a Series A round that closed earlier this year.